We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
NobrXiol™, an intranasal cannabidiol product candidate for the treatment of epilepsy in both children and adults, has received pre-investigational new drug (PIND) guidance from the FDA.
